Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

NCT03781960 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Safety letter from sponsor

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Abemaciclib
DRUG: Nivolumab

Sponsor

Abramson Cancer Center at Penn Medicine